Incyte Corporation Earnings Conference Call (Q1 2014) Today's Calls 
Visit the TF Network Sites
Visit the TF Network Sites
· Corporate IR Center
· Institutional Investor Center
· Individual Investor Center
Download Plug-In
Real Player 8 Basic
Windows Media Player
Other Conference Calls
Other May 1 Calls
Today's Calls
Call Details
Incyte Corporation Earnings Conference Call (Q1 2014)
Scheduled to start Thu, May 1, 2014, 8:30 am Eastern

Check back at the scheduled start time for
the audio link to appear in this spot.

Add this event to your Yahoo! Calendar Add This Event To Your Yahoo! Calendar


About Incyte Corp (NasdaqGS:INCY)
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs primarily for oncology and inflammation. The company markets JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, a JAK inhibitor, which is in Phase III clinical trial for polycythemia vera; in Phase II trial for pancreatic cancer; and in Phase I trial for the treatment of malignancies, as well as baricitinib, a JAK inhibitor, which is in Phase III trial for rheumatoid arthritis, in Phase IIb trial for psoriasis, and in Phase II trial for diabetic nephropathy. The company’s products in pipeline also comprise INC280, which is in Phase II clinical trial for the treatment of solid tumors, hepatocellular carcinoma, and non-small cell lung cancer; and INCB24360 that is in Phase II clinical trial for the treatment of metastatic melanoma and ovarian cancer; INCB40093 and INCB39110+INCB40093, which are Phase I clinical trial products for the treatment of B-lymphoid malignancies; INCB39110 that is in Phase II for myelofibrosis treatment and in Phase I for the treatment of malignancies; and INCB47986, which is in Phase I clinical trial products for the treatment of rheumatoid arthritis. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc., as well as strategic collaboration arrangement with Merck. The company was founded in 1991 and is headquartered in Wilmington, Delaware.


More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings


Copyright © 2014 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Copyright © 2014 FirstCall Events. Historical chart data provided by Commodity Systems, Inc. (CSI). Company profile information presented on this page is Copyright Capital IQ. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.